Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 15/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.33 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5399820 | 0.90 | ALDH1A1 (0.35) | PTPN2PTPN1TACR1ALDH1A1GAA | |
| SCHEMBL5408355 | 0.88 | PTPN2 (0.35) | PTPN2PTPN1TACR1 | |
| SCHEMBL5414183 | 0.88 | TSHR (0.38) | PTPN2PTPN1 | |
| SCHEMBL5396793 | 0.82 | PTPN1 (0.35) | PTPN2PTPN1ALDH1A1 | |
| SCHEMBL5395164 | 0.81 | CETP (0.43) | — | |
| SCHEMBL5404413 | 0.80 | FFAR4 (0.36) | PTPN2PTPN1ALDH1A1 | |
| SCHEMBL7204587 | 0.80 | PTPN1 (0.35) | PTPN2PTPN1ALDH1A1GAAPKM | |
| SCHEMBL5390873 | 0.79 | NPC1 (0.35) | ALDH1A1GAAPKM | |
| SCHEMBL5468254 | 0.78 | CYSLTR1 (0.38) | PTPN2PTPN1 | |
| SCHEMBL7592249 | 0.78 | ALDH1A1 (0.35) | PTPN2PTPN1ALDH1A1GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163932-B2 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA & CO. (CA) | 2007-01-16 | — | — | US | disclosed |
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | MERCK FROSST CANADA LTD. (CA) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176330-A1 | Aryldifluoromethylphosphonic acids for treatment of diabetes | PTPRF, PTPRO, PTP4A1 | PTPN2 27/4885PTPN1 16/4885TACR1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.